Strategy for Oligometastatic Recurrence of Cardia Adenocarcinoma: Liver Radiofrequency Ablation Associated with PIPAC Inducing Response Permitting Cytoreductive Surgery and HIPEC
Tóm tắt
Management of oligometastatic disease (OMD) in esophagogastric junction cancer is complex due to anatomical location and adenocarcinoma pathway. Specific curative strategy is mandatory to increase survival. A multimodal approach combining surgery, systemic and peritoneal chemotherapy, radiotherapy, and radiofrequency could be envisaged. We report a strategy proposed for a 61-year-old male with cardia adenocarcinoma, initially treated with chemotherapy and superior polar esogastrectomy. He developed at later stage an OMD with peritoneal metastasis, single liver metastasis, and single lung metastasis. Considering that peritoneal metastases were unresectable at first, he was given multiple Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin, associated with intravenous docetaxel. Percutaneous radiofrequency ablation was performed during the first PIPAC procedure. Peritoneal response allowed a secondary Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Tài liệu tham khảo
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
Jamel S, Tukanova K, Markar S (2019) Detection and management of oligometastatic disease in oesophageal cancer and identification of prognostic factors: a systematic review. World J Gastrointest Oncol 11(9):741–749. https://doi.org/10.4251/wjgo.v11.i9.741
Mönig S, van Hootegem S, Chevallay M, Wijnhoven B (2018) The role of surgery in advanced disease for esophageal and junctional cancer. Best Pract Res Clin Gastroenterol 36–37:91–96. https://doi.org/10.1016/j.bpg.2018.11.002
Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8–10. https://doi.org/10.1200/JCO.1995.13.1.8
Huddy JR, Thomas RL, Worthington TR, Karanjia ND (2015) Liver metastases from esophageal carcinoma: is there a role for surgical resection? Dis Esophagus 28(5):483–487. https://doi.org/10.1111/dote.12233
Yamamoto T, Tachibana M, Kinugasa S, Yoshimura H, Nagasue N (2001) Esophagectomy and hepatic arterial chemotherapy following hepatic resection for esophageal cancer with liver metastasis. J Gastroenterol 36(8):560–563. https://doi.org/10.1007/s005350170060
Bonnot PE, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, Bereder JM, Abboud K, Marchal F, Quenet F, Goere D, Msika S, Arvieux C, Pirro N, Wernert R, Rat P, Gagnière J, Lefevre JH, Courvoisier T, Kianmanesh R, Vaudoyer D, Rivoire M, Meeus P, Passot G, Glehen O, FREGAT and BIG-RENAPE Networks (2019) Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol 37(23):2028–2040. https://doi.org/10.1200/JCO.18.01688
Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I (2014) Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol 110(3):275–284. https://doi.org/10.1002/jso.23633
Alyami M, Mercier F, Siebert M, Bonnot PE, Laplace N, Villeneuve L, Passot G, Glehen O, Bakrin N, Kepenekian V (2021) Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 47(1):128–133. https://doi.org/10.1016/j.ejso.2019.06.028
Iijima Y, Akiyama H, Atari M, Fukuhara M, Nakajima Y, Kinosita H, Uramoto H (2016) Pulmonary resection for metastatic gastric cancer. Ann Thorac Cardiovasc Surg 22(4):230–236. https://doi.org/10.5761/atcs.oa.16-00049
Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, Schmalenberg H, Luley KB, Prasnikar N, Egger M, Probst S, Messmann H, Moehler M, Fischbach W, Hartmann JT, Mayer F, Höffkes HG, Koenigsmann M, Arnold D, Kraus TW, Grimm K, Berkhoff S, Post S, Jäger E, Bechstein W, Ronellenfitsch U, Mönig S, Hofheinz RD (2017) Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol 3(9):1237–1244. https://doi.org/10.1001/jamaoncol.2017.0515
Al-Batran SE, Goetze TO, Mueller DW et al (2017) The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer 17(1):893. https://doi.org/10.1186/s12885-017-3918-9
Pocard M, Mirshahi M, Therwath A (2021) The hallmarks of oligometastatic diseases: solution for the treatment dilemma. Surg Open Dig Adv 2:100012. https://doi.org/10.1016/j.soda.2021.100012